New and more effective application assays for hemostatic disorder assessment: A systematic review

Abstract

Background: Hemostasis research lacked novel platform assays for hemostatic disorder diagnosis. The current review study’s goal is to compare various assays for evaluating the novel hemostatic techniques used in the diagnosis of coagulation disturbances and to highlight each method’s strongest and weakest points. Methods: The PRISMA guidelines and the recommendations for observational studies in epidemiology were both followed in the current systematic review. The PRISMA-compliant electronic databases (PubMed), a novel platform for evaluating hemostasis, were searched using the keywords. The electronic databases (PubMed), a cutting-edge platform to assess hemostasis, were searched using the keywords. Articles published between December 2016 and December 2021 were only included in searches; original articles were written in English. In order to assess hemostasis studies, we gathered bibliographies of abstracts that were published on the new and more effective application assays for assessments of hemostasis disorders. Results: Following the removal of duplicates, articles were determined by examining the titles and abstracts. Disagreements were resolved through consensus and the application of novel hemostatic analysis methods. Then independently reviewed the relevant studies of the recognized records (n=503), excluding duplicates (n=9) and irrelevant studies (n=249). The remaining 254 studies were read in their entirety, the data from the seven included studies had been extracted. Conclusions: When expressed as an anticoagulant for the in vivo assessment of on the complement system, nanotechnology-based study was more effective in some laboratory tests, and flow cytometer evaluation could be a promising platform approach for use in hemostasis management.